{"id":"W4210332821","doi":"10.1016/s1470-2045(21)00757-9","title":"Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":186,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of British Columbia","funders":"Janssen Biotech; Daiichi Sankyo Europe; National Cancer Institute; Pharmacyclics; Stand Up To Cancer; Janssen Research and Development; EMD Serono; Genentech; Ipsen; Astellas Pharma; Daiichi-Sankyo; Seagen; Pfizer; Incyte; National Institutes of Health; Menarini Silicon Biosystems; Eli Lilly and Company; U.S. Department of Defense; Sanofi; Exelixis; Flatiron Health; Advanced Accelerator Applications; Endocyte; Prostate Cancer Foundation; Bristol-Myers Squibb; AstraZeneca; American Association for Cancer Research; Amgen","keywords":"Prostate cancer; DNA repair; Gene; DNA; DNA Damage Repair; Phase (matter); Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001441823,0.001806794,0.002122601,0.0003240936,0.0003048283,0.001304831,0.0007455748,0.001327816,0.00378642],"category_scores_gemma":[0.001179257,0.0005336697,0.002011747,0.0004624435,0.001050728,0.001112091,0.0004371858,0.003728747,0.0008711432],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007584925,"about_ca_system_score_gemma":0.000917365,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007362738,"about_ca_topic_score_gemma":0.002106424,"domain_scores_codex":[0.9995095,0.0002609412,0.00001539081,0.00009078756,0.00003615118,0.00008738918],"domain_scores_gemma":[0.9995685,0.0001022002,0.00007613879,0.00003730913,0.00002263056,0.0001932141],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8847294,0.009054312,0.002374056,0.001212494,0.002509396,0.00017494,0.0001622308,0.002237904,0.009555012,0.0004174686,0.003838838,0.08373396],"study_design_scores_gemma":[0.9086898,0.08259355,0.003757072,0.0000501167,0.0005213401,0.0002237871,0.00005274713,0.0009170555,0.0005727515,0.0004711644,0.002112047,0.00003860911],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9824138,0.008894555,0.0007793162,0.001525076,0.0005218477,0.001255592,0.001420072,0.000188228,0.003001586],"genre_scores_gemma":[0.9854579,0.004980274,0.001449366,0.001758937,0.0002907153,0.001006427,0.001862584,0.00004186426,0.003151906],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00378642,"threshold_uncertainty_score":0.01266682,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08052415143704984,"score_gpt":0.3979720798969069,"score_spread":0.317447928459857,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}